InspireMD Amends Series J/K Warrants: $11M Potential Proceeds Tied to FDA Approval
NSPR sits 22% above its 52-week low of $0.63 on light trading volume (0.3× avg).
Summary
InspireMD amended existing Series J and K warrants to align exercise with anticipated FDA approval of CGuard Prime 80 cm, potentially raising up to $11 million to fund the product launch.
Key Events · Financing and Capital Events · NSPR
-
Warrant Amendments Align with FDA Milestone
InspireMD amended Series J and K warrants to lower the exercise price to $0.7674 and extend the termination date to May 15, 2028 or 20 trading days after FDA approval of CGuard Prime 80 cm.
-
Potential $11M Gross Proceeds
If exercised in full, the amended warrants covering ~4.8M Series J and 9.5M Series K shares could generate up to $11 million in gross proceeds to fund the CGuard Prime 80 cm launch.
-
No New Warrants Issued
The amendments do not include issuance of any additional warrants or shares, so there is no incremental dilution beyond the existing warrant overhang.
-
Going Concern and Delisting Backdrop
The financing mechanism is critical given the company's going-concern warning and Nasdaq delisting notice received in July 2026.
Analysis · NSPR · Industrial Applications And Services
InspireMD amended existing Series J and K warrants to lower the exercise price to $0.7674 and extend the termination date to May 15, 2028 or 20 trading days after FDA approval of CGuard Prime 80 cm. The amendments cover approximately 4.8 million Series J shares and 9.5 million Series K shares, potentially generating up to $11 million in gross proceeds if exercised in full. This capital would fund the commercial launch of CGuard Prime 80 cm following anticipated Q4 2026 FDA approval. The company faces a going-concern warning and a Nasdaq delisting notice, so this financing mechanism is critical to extending its runway. No new warrants were issued, so there is no incremental dilution beyond the existing warrant overhang.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1625 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NSPR was trading at $0.77 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $35.7M. The 52-week trading range was $0.63 to $2.57. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.